GranzaBio is a company that focuses on the development of innovative solutions in the field of biotechnology, aiming to contribute to advancements in healthcare and life sciences.

GranzaBio

Granza Bio is a biotechnology company developing a novel delivery “shell” platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system’s powerful suite of weapons, “attack particles”. Utilizing their advanced delivery platform, they aim to target these "attack particles" against a range of diseases such as cancer, autoimmune disorders, and infections. Interested to know more? 


Granza Bio (YC W24)

We're currently seeking an exceptional research scientist to join our team at Granza Bio (YC W24). If you or anyone in your network knows a suitable candidate, feel free to reach out to me 😃

Excited to announce that Dr. Lina Chen is joining Granza Bio as a Scientist!

Lina brings over 10 years of research expertise in academia focusing on molecular biology and protein production! Welcome to the team, Lina ⚡️😄

Granza Bio (YC W24) Wednesdays are for cloning 🤓💥

Great to see our logo light up Times Square! Thank you Brex

Excited to announce that Dr. Gaurav Gupta  is joining Granza Bio as Vice President of Research and Development (R&D)! 

Gaurav brings more than 20 years' expertise in academia and industry, with a particular focus on Immunology. He has worked across the full spectrum of pharmaceutical R&D, from conceptualization to clinical trials and market launch. 

Gaurav's notable achievements include contributing to process developments of the AstraZeneca COVID-19 vaccine and the Malaria Vaccine at the Jenner Institute at the University of Oxford.

Welcome to the team, Gaurav ⚡️😄

Exited to share that recent Oxford DPhil graduate and founder at Granza Bio (YC W24), Ashwin Jainarayanan, has been named one of the 2024 Schmidt Science Fellows. Congratulations Ashwin!

COM:GRANZABIO

GranzaBio

Financials Not Available